Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Inclusion Criteria:

   - Patients must be enrolled on ANBL00B1 (NCT00904241) or APEC14B1 (NCT02402244) prior to
   enrollment on ANBL1531 (NCT03126916)

   - Patient must be >= 365 days and =< 30 years of age at diagnosis

   - Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular)
   verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone
   marrow with elevated urinary catecholamine metabolites; the following disease groups
   are eligible:

      - Patients with International Neuroblastoma Risk Group (INRG) stage M disease are
      eligible if found to have either of the following features:

         - MYCN amplification (> 4-fold increase in MYCN signals as compared to
         reference signals), regardless of additional biologic features; OR

         - Age > 547 days regardless of biologic features

      - Patients with INRG stage MS disease with MYCN amplification

      - Patients with INRG stage L2 disease with MYCN amplification

      - Patients > 547 days of age initially diagnosed with INRG stage L1, L2 or MS
      disease who progressed to stage M without prior chemotherapy may enroll within 4
      weeks of progression to stage M

      - Patients >= 365 days of age initially diagnosed with MYCN amplified INRG stage L1
      disease who progress to stage M without systemic therapy may enroll within 4
      weeks of progression to stage M

   - Patients initially recognized to have high-risk disease must have had no prior
   systemic therapy (other than topotecan/cyclophosphamide initiated on an emergent basis
   and within allowed timing); patients observed or treated with a single cycle of
   chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per
   ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high risk disease
   but subsequently found to meet the criteria will also be eligible; patients who
   receive localized emergency radiation to sites of life-threatening or
   function-threatening disease prior to or immediately after establishment of the
   definitive diagnosis will be eligible

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows:

      - 1 to < 2 years: male = 0.6; female = 0.6

      - 2 to < 6 years: male = 0.8; female = 0.8

      - 6 to < 10 years: male = 1; female = 1

      - 10 to < 13 years: male = 1.2; female = 1.2

      - 13 to < 16 years: male = 1.5; female = 1.4

      - >= 16 years: male = 1.7; female = 1.4

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 10 x
   ULN; for the purposes of this study, ULN for SGPT (ALT) is 45

   - Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by
   echocardiogram or radionuclide angiogram

   - No known contraindication to peripheral blood stem cell (PBSC) collection; examples of
   contraindications might be a weight or size less than the collecting institution finds
   feasible, or a physical condition that would limit the ability of the child to undergo
   apheresis catheter placement (if necessary) and/or the apheresis procedure

Exclusion Criteria:

   - Patients with INRG stage L2 tumors without amplification of MYCN regardless of tumor
   histology (may meet criteria for high risk classification but are not eligible for
   this trial)

   - Patients with bone marrow failure syndromes

   - Patients for whom targeted radiopharmaceutical therapy would be contraindicated due to
   underlying medical disorders

   - Female patients who are pregnant since fetal toxicities and teratogenic effects have
   been noted for several of the study drugs; a pregnancy test is required for female
   patients of childbearing potential

   - Lactating females who plan to breastfeed their infants

   - Sexually active patients of reproductive potential who have not agreed to use an
   effective contraceptive method for the duration of their study participation